A5061755960- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- RNA modifications and cancer
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Hepatitis B Virus Studies
- Cancer Mechanisms and Therapy
- Liver Disease Diagnosis and Treatment
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Colorectal Cancer Treatments and Studies
- Renal cell carcinoma treatment
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Immunotherapy and Biomarkers
- Cancer, Hypoxia, and Metabolism
- CAR-T cell therapy research
- Cancer, Lipids, and Metabolism
- Photodynamic Therapy Research Studies
- Epigenetics and DNA Methylation
- Liver Disease and Transplantation
- Lung Cancer Diagnosis and Treatment
- Pharmacogenetics and Drug Metabolism
- Nonmelanoma Skin Cancer Studies
- Medicinal Plant Pharmacodynamics Research
Southern Medical University
2012-2025
Nanfang Hospital
2012-2025
Quanzhou Normal University
2021
Nanjing Drum Tower Hospital
2009
Background There is no study accessible now assessing the prognostic aspect of radiomics for anti-PD-1 therapy patients with HCC. Aim The aim this was to develop and validate a nomogram by incorporating pretreatment contrast-enhanced Computed tomography (CT) images clinical risk factors estimate treatment efficacy in Hepatocellular Carcinoma (HCC) patients. Methods A total 58 advanced HCC who were refractory standard first-line therapy, received PD-1 inhibitor Toripalimab, Camrelizumab, or...
Abstract Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC essential for the development novel therapeutics. Here, we constructed two independent cohorts from clinic centers. A comprehensive multiomics analysis via proteomic, whole-exome sequencing (WES), single-cell RNA (scRNA-seq) was performed. Novel subtypes were derived in training cohort (n =...
Abstract Background Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit its combination with immunotherapy needs to be verified. This study evaluated efficacy and safety tislelizumab plus lenvatinib systemic treatment-naïve patients uHCC. Methods In this multicenter, single-arm, phase 2 study, uHCC received 200 mg every three weeks (bodyweight ≥ 60 kg: 12 mg; < 8 once daily). Dose-limiting toxicities (DLTs) were run-in determine whether...
Abstract Strategies to improve T cell therapy efficacy in solid tumors such as hepatocellular carcinoma (HCC) are urgently needed. The common cytokine receptor γ chain (γ c ) family cytokines IL-2, IL-7, IL-15 and IL-21 play fundamental roles development, differentiation effector phases. This study aims determine the combination effects of against HCC investigate optimized strategies utilize effect signal therapy. antitumor function AFP-specific receptor-engineered cells (TCR-T) was...
Aberrant microRNA expression has been implicated in metastasis of cancers. MiR-661 accelerates proliferation and invasion breast cancer ovarian cancer, while impedes that glioma. Its role non small cell lung (NSCLC) underlying mechanism are worthy elucidation. Expression miR-661 was measured with real-time PCR both NSCLC tissues lines. The effects on migration, capacity were evaluated using wound healing, transwell assay animal models. Dual reporter luciferase complementary experiments...
Abstract Background Depression is a common, easily ignored, accompanied disease of gastric cancer (GC) patients and often observed with elevated plasma catecholamine levels. frequently promotes GC progression leads to poor clinical outcomes; however, the molecular mechanisms underlying depression‐induced remain poorly understood. We aimed study effects depression on explore possible mediating action depression‐associated catecholamines GC. Methods states were graded using Patient Health...
Combining an antiangiogenic agent with anti-PD-1 is a promising strategy for unresectable hepatocellular carcinoma (HCC).To explore the effectiveness and tolerability of lenvatinib plus camrelizumab vs. monotherapy as first-line treatment HCC.This multicenter, retrospective cohort study included patients HCC treated oral 8 mg daily intravenous 200 every 3 weeks (L+C group) or 12 (L in four Chinese centers between September 2018 February 2020. Tumor response was evaluated according to RECIST...
Background: The clinical significance of programmed cell death protein-1 (PD-1)-targeted immunotherapy in Chinese patients is understudied. We thus aimed to evaluate the safety and efficacy PD-1 inhibitors with toripalimab, camrelizumab or sintilimab for hepatocellular carcinoma (HCC) a real-life cohort. Methods: analysed hepatitis B virus (HBV)-associated HCC treated camrelizumab, retrospective single-center cohort from November 2018 June 2020. Efficacy was evaluated objective response rate...
Previous trials demonstrated that anti-angiogenesis or anti-programmed death protein 1 (PD-1) monotherapy showed unsatisfied effect in advanced hepatocellular carcinoma (HCC). No study existed focus on the effects of camrelizumab and apatinib ("C+A") combination therapy for HCC patients with location extent portal vein tumor thrombus (PVTT) as main variable being assessed. This was to compare efficacy tolerability "C+A" PVTT.We retrospectively analyzed PVTT who underwent a multicenter...
533 Background: To develop and validate a predictive model to identify hepatocellular carcinoma (HCC) patients likely benefit from combined treatment of transarterial chemoembolization (TACE), molecular targeted therapies (MTTs), immune checkpoint inhibitors (ICIs). Methods: Data 500 with unresectable HCC treated TACE, MTTs, ICIs (2019-2023) were analyzed. Patients divided into training set (241 Nanfang Hospital) validation (259 various hospitals). Key prognostic variables identified using...
ABSTRACT Background and Aims The impact of low‐level viremia(LLV) on the efficacy immune checkpoint inhibitors (ICIs) in unresectable hepatocellular carcinoma(uHCC) patients remains unclear. This study aims to investigate effect LLV outcomes ICIs‐based therapy with uHCC. Methods In this multicenter retrospective study, we included uHCC who received at four centres between January 2019 December 2022. All were positive for HBsAg nucleos(t)ide analogues (NAs) antiviral therapy. Propensity score...
Despite the epidemiological association between intrahepatic cholangiocarcinoma (ICC) and hepatitis B virus (HBV) infection, little is known about relevant oncogenic effects. A cohort of 32 HBV-infected ICC 89 non-HBV-ICC patients were characterized using whole-exome sequencing, proteomic analysis, single-cell RNA sequencing. Proteomic analysis revealed decreased cell-cell junction levels in HBV-ICC patients. The level had an inverse relationship with epithelial-mesenchymal transition (EMT)...
Abstract Background Alterations in histone modifications have been reported to be related tumorigenicity and tumor progression. However, whether modification can aid the classification of patients or influence clinical behavior with colon cancer remains unclear. Therefore, this study aimed evaluate modifier expression patterns using unsupervised clustering transcriptomic expressions 88 acetylation methylation regulators. Results In study, by consensus analysis based on transcriptome data...
A high baseline hepatitis B virus (HBV) load has always been listed as an exclusion criterion for programmed cell death-1 (PD-1) inhibitor-associated therapy in clinical trials, the interaction between HBV and anti-PD-1/PD-L1 with anti remains controversial.We retrospectively enrolled 70 unresectable HCC patients who were seropositive HBsAg accepted tenofovir alafenamide fumarate (TAF) before anti-PD-1 combination antiangiogenic treatment. Patients divided into a low DNA group (≤ 2000 IU/ml)...
e16128 Background: The combination of systemic therapies and hepatic arterial infusion chemotherapy (HAIC) showed promising outcomes for advanced hepatocellular carcinoma (HCC). Raltitrexed, an antimetabolic drug with long plasma concentrations half-life, could be used in short infusions. HAIC raltitrexed plus oxaliplatin (RALOX) was reported to effective safe HCC. This study aimed investigate the efficacy safety combined camrelizumab lenvatinib RALOX-HAIC as a first-line treatment HCC...
Summary Background Esophagogastroduodenoscopy (EGD) is required to screen for high‐risk varices (HRV) in patients with hepatocellular carcinoma (HCC), especially since overall survival rates have dramatically improved new systemic therapies. Aim To assess the Baveno VI and VII algorithms' ability rule out HRV hepatitis B virus (HBV)‐related HCC Methods We prospectively enrolled consecutive HBV related, compensated cirrhosis newly diagnosed who underwent liver stiffness measurement, spleen...
Abstract Objectives To explore the efficacy and safety of Transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) tyrosine kinase (TKIs) patients unresectable hepatocellular carcinoma (uHCC). Methods 456 HCC receiving either TACE ICIs TKIs (combination group, n = 139) or monotherapy (monotherapy 317) were included from Apr 2016 to Dec 2021 this retrospective study. We employed propensity score matching (PSM), performed 1:2 optimal pair matching, balance...
ABSTRACT Lenvatinib has been demonstrated effective in advanced hepatocellular carcinoma (HCC), but the pharmacokinetic–pharmacodynamics behavior of lenvatinib and its metabolites remains unclear. To investigate active HCC patients, it is important to develop a simple rapid method analyze exposures human samples. Here, we established validated for determining three major metabolites, descyclopropyl (M1), O‐demethyl hydrochloride (M2), N‐Oxide (M3) by liquid chromatography‐tandem mass...
The clinical significance of liver stiffness (LS) measured by shear wave elastography (SWE) in programmed cell death protein-1 (PD-1) inhibitors treated advanced hepatocellular carcinoma (HCC) patients remains unknown. This study aimed to explore the prognostic value baseline LS SWE prior PD-1 inhibitor treatment combination with lenvatinib.We retrospectively evaluated (n=133) HCC who received anti-PD-1 antibodies plus lenvatinib at two high-volume medical centres, between January 2020 and...